Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Opioid Analgesic
1.3.3 Calcium Channel Blocker
1.3.4 Anticonvulsant
1.3.5 Stool Softener
1.3.6 Osmotic Agent
1.3.7 Other Drugs
1.4 Market Segment by Application
1.4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital
1.4.3 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2015-2026)
2.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2015-2026)
2.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (2015-2026)
2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Regions (2015-2020)
2.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Regions (2015-2020)
2.3 Global Top Aneurysmal Subarachnoid Hemorrhage Drugs Regions (Countries) Ranking by Market Size
2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends
2.4.1 Aneurysmal Subarachnoid Hemorrhage Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Aneurysmal Subarachnoid Hemorrhage Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Aneurysmal Subarachnoid Hemorrhage Drugs Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Aneurysmal Subarachnoid Hemorrhage Drugs Sales in 2019
3.2 Global Top Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs by Revenue
3.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Aneurysmal Subarachnoid Hemorrhage Drugs as of 2019)
3.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Aneurysmal Subarachnoid Hemorrhage Drugs Market
3.7 Key Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price by Type (2015-2020)
4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price Forecast by Type (2021-2026)
5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Application
5.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price by Application (2015-2020)
5.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
6.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
6.3 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
6.4 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
6.4.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
6.4.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
7.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
7.3 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
7.4 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
7.4.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
7.4.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
8.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
8.3 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
8.4 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Regions
8.4.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
9.2 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
9.3 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
9.4 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
9.4.1 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
9.4.2 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
10.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
10.3 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
10.3.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Arbor Pharmaceuticals
11.1.1 Arbor Pharmaceuticals Corporation Information
11.1.2 Arbor Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.1.5 Arbor Pharmaceuticals SWOT Analysis
11.1.6 Arbor Pharmaceuticals Recent Developments
11.2 Edge Therapeutics
11.2.1 Edge Therapeutics Corporation Information
11.2.2 Edge Therapeutics Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Edge Therapeutics Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Edge Therapeutics Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.2.5 Edge Therapeutics SWOT Analysis
11.2.6 Edge Therapeutics Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Johnson & Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Johnson & Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.3.5 Johnson & Johnson SWOT Analysis
11.3.6 Johnson & Johnson Recent Developments
11.4 Mylan N.V
11.4.1 Mylan N.V Corporation Information
11.4.2 Mylan N.V Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.4.5 Mylan N.V SWOT Analysis
11.4.6 Mylan N.V Recent Developments
11.5 Orexo AB
11.5.1 Orexo AB Corporation Information
11.5.2 Orexo AB Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.5.5 Orexo AB SWOT Analysis
11.5.6 Orexo AB Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.6.5 Pfizer SWOT Analysis
11.6.6 Pfizer Recent Developments
11.7 Purdue Pharma
11.7.1 Purdue Pharma Corporation Information
11.7.2 Purdue Pharma Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.7.5 Purdue Pharma SWOT Analysis
11.7.6 Purdue Pharma Recent Developments
11.8 Pharmaxis
11.8.1 Pharmaxis Corporation Information
11.8.2 Pharmaxis Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.8.5 Pharmaxis SWOT Analysis
11.8.6 Pharmaxis Recent Developments
11.9 Sun Pharmaceutical Industries
11.9.1 Sun Pharmaceutical Industries Corporation Information
11.9.2 Sun Pharmaceutical Industries Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.9.5 Sun Pharmaceutical Industries SWOT Analysis
11.9.6 Sun Pharmaceutical Industries Recent Developments
11.10 Teva Pharmaceutical
11.10.1 Teva Pharmaceutical Corporation Information
11.10.2 Teva Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.10.5 Teva Pharmaceutical SWOT Analysis
11.10.6 Teva Pharmaceutical Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Aneurysmal Subarachnoid Hemorrhage Drugs Sales Channels
12.2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Distributors
12.3 Aneurysmal Subarachnoid Hemorrhage Drugs Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.2.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.2.3 North America Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.3.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Arbor Pharmaceuticals、Edge Therapeutics、Johnson & Johnson、Mylan N.V、Orexo AB、Pfizer、Purdue Pharma、Pharmaxis、Sun Pharmaceutical Industries、Teva Pharmaceutical
【免責事項】
https://www.globalresearch.jp/disclaimer